These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 11829717

  • 1. Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer.
    Koutsilieris M, Mitsiades C, Dimopoulos T, Vacalicos J, Lambou T, Tsintavis A, Milathianakis C, Bogdanos J, Karamanolakis D.
    Expert Opin Investig Drugs; 2002 Feb; 11(2):283-93. PubMed ID: 11829717
    [Abstract] [Full Text] [Related]

  • 2. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
    Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T.
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [Abstract] [Full Text] [Related]

  • 4. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 5. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M, Dimopoulos T, Milathianakis C, Bogdanos J, Karamanolakis D, Pissimissis N, Halapas A, Lembessis P, Papaioannou A, Sourla A.
    BJU Int; 2007 Jul 01; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract] [Full Text] [Related]

  • 6. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.
    Koutsilieris M, Tzanela M, Dimopoulos T.
    Prostate; 1999 Mar 01; 38(4):313-6. PubMed ID: 10075011
    [Abstract] [Full Text] [Related]

  • 7. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.
    Bogdanos J, Karamanolakis D, Tenta R, Tsintavis A, Milathianakis C, Mitsiades C, Koutsilieris M.
    Endocr Relat Cancer; 2003 Jun 01; 10(2):279-89. PubMed ID: 12790789
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
    Di Silverio F, Sciarra A.
    J Urol; 2003 Nov 01; 170(5):1812-6. PubMed ID: 14532782
    [Abstract] [Full Text] [Related]

  • 9. Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC).
    Mitsogiannis IC, Skolarikos A, Deliveliotis C.
    Expert Opin Pharmacother; 2009 Feb 01; 10(3):493-501. PubMed ID: 19191684
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
    Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M.
    Urology; 2004 Jan 01; 63(1):120-5. PubMed ID: 14751362
    [Abstract] [Full Text] [Related]

  • 13. Endocrine therapy of prostate cancer.
    Bare RL, Torti FM.
    Cancer Treat Res; 1998 Jan 01; 94():69-87. PubMed ID: 9587683
    [Abstract] [Full Text] [Related]

  • 14. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
    Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M.
    Anticancer Res; 2006 Jan 01; 26(5B):3693-700. PubMed ID: 17094387
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.
    Sciarra A, Bosman C, Monti G, Gentile V, Autran Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F.
    J Urol; 2004 Nov 01; 172(5 Pt 1):1775-83. PubMed ID: 15540720
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Current treatment of advanced prostate cancer.
    Ismail M, Gomella LG.
    Tech Urol; 1997 Nov 01; 3(1):16-24. PubMed ID: 9170220
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.